Advances in NSAID development: Evolution of diclofenac products using pharmaceutical technology

Roy D Altman, Bill Bosch, Kay Brune, Paola Patrignani, Clarence Young

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) of the phenylacetic acid class with anti-inflammatory, analgesic, and antipyretic properties. Contrary to the action of many traditional NSAIDs, diclofenac inhibits cyclooxygenase (COX)-2 enzyme with greater potency than it does COX-1. Similar to other NSAIDs, diclofenac is associated with serious dose-dependent gastrointestinal, cardiovascular, and renal adverse effects. Since its introduction in 1973, a number of different diclofenac-containing drug products have been developed with the goal of improving efficacy, tolerability, and patient convenience. Delayed- and extended-release forms of diclofenac sodium were initially developed with the goal of improving the safety profile of diclofenac and providing convenient, once-daily dosing for the treatment of patients with chronic pain. New drug products consisting of diclofenac potassium salt were associated with faster absorption and rapid onset of pain relief. These include diclofenac potassium immediate-release tablets, diclofenac potassium liquid-filled soft gel capsules, and diclofenac potassium powder for oral solution. The advent of topical formulations of diclofenac enabled local treatment of pain and inflammation while minimizing systemic absorption of diclofenac. SoluMatrix diclofenac, consisting of submicron particles of diclofenac free acid and a proprietary combination of excipients, was developed to provide analgesic efficacy at reduced doses associated with lower systemic absorption. This review illustrates how pharmaceutical technology has been used to modify the pharmacokinetic properties of diclofenac, leading to the creation of novel drug products with improved clinical utility.

Original languageEnglish (US)
Pages (from-to)859-877
Number of pages19
JournalDrugs
Volume75
Issue number8
DOIs
StatePublished - May 12 2015
Externally publishedYes

Fingerprint

Pharmaceutical Technology
Diclofenac
Anti-Inflammatory Agents
Pharmaceutical Preparations
Non-Steroidal Anti-Inflammatory Agents
Pain
Antipyretics
Cyclooxygenase 1
Excipients

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Advances in NSAID development : Evolution of diclofenac products using pharmaceutical technology. / Altman, Roy D; Bosch, Bill; Brune, Kay; Patrignani, Paola; Young, Clarence.

In: Drugs, Vol. 75, No. 8, 12.05.2015, p. 859-877.

Research output: Contribution to journalArticle

Altman, RD, Bosch, B, Brune, K, Patrignani, P & Young, C 2015, 'Advances in NSAID development: Evolution of diclofenac products using pharmaceutical technology', Drugs, vol. 75, no. 8, pp. 859-877. https://doi.org/10.1007/s40265-015-0392-z
Altman, Roy D ; Bosch, Bill ; Brune, Kay ; Patrignani, Paola ; Young, Clarence. / Advances in NSAID development : Evolution of diclofenac products using pharmaceutical technology. In: Drugs. 2015 ; Vol. 75, No. 8. pp. 859-877.
@article{721d9943fefc4407980f627142d02536,
title = "Advances in NSAID development: Evolution of diclofenac products using pharmaceutical technology",
abstract = "Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) of the phenylacetic acid class with anti-inflammatory, analgesic, and antipyretic properties. Contrary to the action of many traditional NSAIDs, diclofenac inhibits cyclooxygenase (COX)-2 enzyme with greater potency than it does COX-1. Similar to other NSAIDs, diclofenac is associated with serious dose-dependent gastrointestinal, cardiovascular, and renal adverse effects. Since its introduction in 1973, a number of different diclofenac-containing drug products have been developed with the goal of improving efficacy, tolerability, and patient convenience. Delayed- and extended-release forms of diclofenac sodium were initially developed with the goal of improving the safety profile of diclofenac and providing convenient, once-daily dosing for the treatment of patients with chronic pain. New drug products consisting of diclofenac potassium salt were associated with faster absorption and rapid onset of pain relief. These include diclofenac potassium immediate-release tablets, diclofenac potassium liquid-filled soft gel capsules, and diclofenac potassium powder for oral solution. The advent of topical formulations of diclofenac enabled local treatment of pain and inflammation while minimizing systemic absorption of diclofenac. SoluMatrix diclofenac, consisting of submicron particles of diclofenac free acid and a proprietary combination of excipients, was developed to provide analgesic efficacy at reduced doses associated with lower systemic absorption. This review illustrates how pharmaceutical technology has been used to modify the pharmacokinetic properties of diclofenac, leading to the creation of novel drug products with improved clinical utility.",
author = "Altman, {Roy D} and Bill Bosch and Kay Brune and Paola Patrignani and Clarence Young",
year = "2015",
month = "5",
day = "12",
doi = "10.1007/s40265-015-0392-z",
language = "English (US)",
volume = "75",
pages = "859--877",
journal = "Drugs",
issn = "0012-6667",
publisher = "Adis International Ltd",
number = "8",

}

TY - JOUR

T1 - Advances in NSAID development

T2 - Evolution of diclofenac products using pharmaceutical technology

AU - Altman, Roy D

AU - Bosch, Bill

AU - Brune, Kay

AU - Patrignani, Paola

AU - Young, Clarence

PY - 2015/5/12

Y1 - 2015/5/12

N2 - Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) of the phenylacetic acid class with anti-inflammatory, analgesic, and antipyretic properties. Contrary to the action of many traditional NSAIDs, diclofenac inhibits cyclooxygenase (COX)-2 enzyme with greater potency than it does COX-1. Similar to other NSAIDs, diclofenac is associated with serious dose-dependent gastrointestinal, cardiovascular, and renal adverse effects. Since its introduction in 1973, a number of different diclofenac-containing drug products have been developed with the goal of improving efficacy, tolerability, and patient convenience. Delayed- and extended-release forms of diclofenac sodium were initially developed with the goal of improving the safety profile of diclofenac and providing convenient, once-daily dosing for the treatment of patients with chronic pain. New drug products consisting of diclofenac potassium salt were associated with faster absorption and rapid onset of pain relief. These include diclofenac potassium immediate-release tablets, diclofenac potassium liquid-filled soft gel capsules, and diclofenac potassium powder for oral solution. The advent of topical formulations of diclofenac enabled local treatment of pain and inflammation while minimizing systemic absorption of diclofenac. SoluMatrix diclofenac, consisting of submicron particles of diclofenac free acid and a proprietary combination of excipients, was developed to provide analgesic efficacy at reduced doses associated with lower systemic absorption. This review illustrates how pharmaceutical technology has been used to modify the pharmacokinetic properties of diclofenac, leading to the creation of novel drug products with improved clinical utility.

AB - Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) of the phenylacetic acid class with anti-inflammatory, analgesic, and antipyretic properties. Contrary to the action of many traditional NSAIDs, diclofenac inhibits cyclooxygenase (COX)-2 enzyme with greater potency than it does COX-1. Similar to other NSAIDs, diclofenac is associated with serious dose-dependent gastrointestinal, cardiovascular, and renal adverse effects. Since its introduction in 1973, a number of different diclofenac-containing drug products have been developed with the goal of improving efficacy, tolerability, and patient convenience. Delayed- and extended-release forms of diclofenac sodium were initially developed with the goal of improving the safety profile of diclofenac and providing convenient, once-daily dosing for the treatment of patients with chronic pain. New drug products consisting of diclofenac potassium salt were associated with faster absorption and rapid onset of pain relief. These include diclofenac potassium immediate-release tablets, diclofenac potassium liquid-filled soft gel capsules, and diclofenac potassium powder for oral solution. The advent of topical formulations of diclofenac enabled local treatment of pain and inflammation while minimizing systemic absorption of diclofenac. SoluMatrix diclofenac, consisting of submicron particles of diclofenac free acid and a proprietary combination of excipients, was developed to provide analgesic efficacy at reduced doses associated with lower systemic absorption. This review illustrates how pharmaceutical technology has been used to modify the pharmacokinetic properties of diclofenac, leading to the creation of novel drug products with improved clinical utility.

UR - http://www.scopus.com/inward/record.url?scp=84930180767&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930180767&partnerID=8YFLogxK

U2 - 10.1007/s40265-015-0392-z

DO - 10.1007/s40265-015-0392-z

M3 - Article

C2 - 25963327

AN - SCOPUS:84930180767

VL - 75

SP - 859

EP - 877

JO - Drugs

JF - Drugs

SN - 0012-6667

IS - 8

ER -